Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Expenses: 2010-2025

Historic Operating Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $731.1 million.

  • Arrowhead Pharmaceuticals' Operating Expenses rose 30.93% to $212.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.1 million, marking a year-over-year increase of 20.92%. This contributed to the annual value of $731.1 million for FY2025, which is 20.92% up from last year.
  • Arrowhead Pharmaceuticals' Operating Expenses amounted to $731.1 million in FY2025, which was up 20.92% from $604.6 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Operating Expenses peaked at $731.1 million during FY2025, and registered a low of $287.3 million during FY2021.
  • For the 3-year period, Arrowhead Pharmaceuticals' Operating Expenses averaged around $593.8 million, with its median value being $604.6 million (2024).
  • Data for Arrowhead Pharmaceuticals' Operating Expenses shows a peak YoY surged of 58.61% (in 2021) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Operating Expenses (Yearly) stood at $287.3 million in 2021, then spiked by 46.78% to $421.7 million in 2022, then grew by 5.69% to $445.7 million in 2023, then spiked by 35.65% to $604.6 million in 2024, then rose by 20.92% to $731.1 million in 2025.